Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 432


3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.


Carbenoxolone as a novel therapy for attenuation of cancer-induced bone pain.

Falk S.

Pain. 2018 Mar 6. doi: 10.1097/j.pain.0000000000001197. [Epub ahead of print]


Structure of the nuclear exosome captured on a maturing preribosome.

Schuller JM, Falk S, Fromm L, Hurt E, Conti E.

Science. 2018 Apr 13;360(6385):219-222. doi: 10.1126/science.aar5428. Epub 2018 Mar 8.


An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded RCT recruitment.

Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A, Stein R, Donovan JL; CSAW study group; Chemorad study group; POUT study group; ACST-2 study group; Optima prelim study group.

J Clin Epidemiol. 2018 Mar 2. pii: S0895-4356(17)31278-7. doi: 10.1016/j.jclinepi.2018.02.018. [Epub ahead of print]


Quality Improvement in Anesthesiology - Leveraging Data and Analytics to Optimize Outcomes.

Valentine EA, Falk SA.

Anesthesiol Clin. 2018 Mar;36(1):31-44. doi: 10.1016/j.anclin.2017.10.006. Review.


Impact of question order on prioritisation of outcomes in the development of a core outcome set: a randomised controlled trial.

Brookes ST, Chalmers KA, Avery KNL, Coulman K, Blazeby JM; ROMIO study group.

Trials. 2018 Jan 25;19(1):66. doi: 10.1186/s13063-017-2405-6.


Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.

Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators.

Lancet Gastroenterol Hepatol. 2017 Dec 15. pii: S2468-1253(17)30394-1. doi: 10.1016/S2468-1253(17)30394-1. [Epub ahead of print]


Reconstitution of the complete pathway of ITS2 processing at the pre-ribosome.

Fromm L, Falk S, Flemming D, Schuller JM, Thoms M, Conti E, Hurt E.

Nat Commun. 2017 Nov 27;8(1):1787. doi: 10.1038/s41467-017-01786-9.


Glial control of neurogenesis.

Falk S, Götz M.

Curr Opin Neurobiol. 2017 Dec;47:188-195. doi: 10.1016/j.conb.2017.10.025. Epub 2017 Nov 13. Review.


Natural and forced neurogenesis: similar and yet different?

Falk S, Karow M.

Cell Tissue Res. 2018 Jan;371(1):181-187. doi: 10.1007/s00441-017-2690-0. Epub 2017 Sep 25. No abstract available.


The CONVERT Trial: Interpretation, Journey and Lessons Learnt.

Faivre-Finn C, Falk S, Blackhall F.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):811-813. doi: 10.1016/j.clon.2017.09.002. Epub 2017 Sep 19. No abstract available.


Frequent PD-L1 Expression in Malignant Melanomas of the Vulva.

Saleh B, Kriegsmann J, Falk S, Aulmann S.

Int J Gynecol Pathol. 2017 Sep 13. doi: 10.1097/PGP.0000000000000454. [Epub ahead of print]


Structural insights into the interaction of the nuclear exosome helicase Mtr4 with the preribosomal protein Nop53.

Falk S, Tants JN, Basquin J, Thoms M, Hurt E, Sattler M, Conti E.

RNA. 2017 Dec;23(12):1780-1787. doi: 10.1261/rna.062901.117. Epub 2017 Sep 7.


Mpp6 Incorporation in the Nuclear Exosome Contributes to RNA Channeling through the Mtr4 Helicase.

Falk S, Bonneau F, Ebert J, Kögel A, Conti E.

Cell Rep. 2017 Sep 5;20(10):2279-2286. doi: 10.1016/j.celrep.2017.08.033.


Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE.

Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4.


First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.

Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.


Expanded Satellite Repeats Amplify a Discrete CENP-A Nucleosome Assembly Site on Chromosomes that Drive in Female Meiosis.

Iwata-Otsubo A, Dawicki-McKenna JM, Akera T, Falk SJ, Chmátal L, Yang K, Sullivan BA, Schultz RM, Lampson MA, Black BE.

Curr Biol. 2017 Aug 7;27(15):2365-2373.e8. doi: 10.1016/j.cub.2017.06.069. Epub 2017 Jul 27.


The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.

Appel CK, Gallego-Pedersen S, Andersen L, Blancheflor Kristensen S, Ding M, Falk S, Sayilekshmy M, Gabel-Jensen C, Heegaard AM.

Sci Rep. 2017 Jul 6;7(1):4792. doi: 10.1038/s41598-017-05029-1.


Grid-climbing Behaviour as a Pain Measure for Cancer-induced Bone Pain and Neuropathic Pain.

Falk S, Gallego-Pedersen S, Petersen NC.

In Vivo. 2017 Jul-Aug;31(4):619-623.


Inhibition of DNA replication in Staphylococcus aureus by tegaserod.

Lacriola CJ, Falk SP, Weisblum B.

J Antibiot (Tokyo). 2017 Jul;70(8):918-920. doi: 10.1038/ja.2017.65. Epub 2017 May 31. No abstract available.


Supplemental Content

Loading ...
Support Center